Repligen (RGEN) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on May 14, 2026, with shareholders of record as of March 16, 2026, eligible to vote.

• Key proposals include electing nine directors, ratifying Ernst & Young LLP as independent auditors for 2026, and an advisory vote on executive compensation.

• Shareholders can vote online, by phone, mail, or during the virtual meeting, and may submit questions during the meeting.

• The company returned to double-digit growth in 2025, with 16% reported and organic growth, expanded margins, and launched new products.

• Notable M&A activity included the acquisition of 908 Devices' PAT portfolio and integration of Tantti, supporting long-term strategy.

Voting matters and shareholder proposals

• Proposal 1: Elect nine directors to serve until the 2027 Annual Meeting.

• Proposal 2: Ratify Ernst & Young LLP as independent auditors for 2026.

• Proposal 3: Advisory vote to approve executive compensation (say-on-pay).

• Shareholders may submit proposals or director nominations for the 2027 meeting, following advance notice procedures.

Board of directors and corporate governance

• Board consists of nine nominees, with a majority being independent and diverse in skills, experience, and demographics.

• Board refreshment continued with recent additions and a new independent Chair, Dr. Madaus, effective March 2026.

• All directors are elected annually by majority vote; proxy access and no super-majority voting requirements are in place.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.

• Annual board and committee evaluations and self-assessments are conducted.